Aeterna Zentaris Inc. (AEZS) |
|
2.97 0.05 (1.71%)
|
06-09 13:41 |
|
Open: |
2.92 |
Pre. Close: |
2.92 |
|
High:
|
2.98 |
Low:
|
2.8501 |
|
Volume:
|
3,782 |
Market Cap:
|
14(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:43:08 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
|
| Target: |
Six months: 3.49 One year: 3.85 |
| Support: |
Support1: 2.5 Support2: 2.07 |
| Resistance: |
Resistance1: 2.99 Resistance2: 3.29 |
| Pivot: |
2.88  |
| Moving Average: |
MA(5): 2.89 MA(20): 2.87
MA(100): 3.09 MA(250): 3.78 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 44.4 %D(3): 53.4 |
| RSI: |
RSI(14): 47.3 |
| 52-week: |
High: 8.75 Low: 2.31 |
| Average Vol(K): |
3-Month: 13 (K) 10-Days: 5 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEZS ] has closed above bottom band by 41.0%. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.99 - 3.01 |
3.01 - 3.02 |
|
Low:
|
2.78 - 2.8 |
2.8 - 2.82 |
|
Close:
|
2.89 - 2.92 |
2.92 - 2.94 |
|
Company Description |
|
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina. |
Headline News |
Mon, 15 May 2023
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders - GlobeNewswire
Tue, 09 May 2023
Aeterna Zentaris Reports First Quarter 2023 Financial Results - GlobeNewswire
Wed, 05 Apr 2023
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin ... - GlobeNewswire
Thu, 23 Mar 2023
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 ... - GlobeNewswire
Thu, 16 Mar 2023
Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the ... - GlobeNewswire
Tue, 17 Jan 2023
Aeterna Zentaris Provides Business Update and Outlines Key ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
0.7 (%) |
|
Shares Short
|
82 (K) |
|
Shares Short P.Month
|
77 (K) |
Stock Financials |
|
EPS
|
-5.04 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.42 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-268.3 |
|
Return on Assets (ttm)
|
-16.5 |
|
Return on Equity (ttm)
|
-57.8 |
|
Qtrly Rev. Growth
|
40.2 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
1.28 |
|
EBITDA (p.s.)
|
-3.45 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-0.57 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.44 |
|
Price to Sales
|
2.21 |
|
Price to Cash Flow
|
-0.86 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
